# q03 rev 1 raw returns (tested_sha256 885ef14edf5cdb5848c63ddc993ab68088bf38ae671c9d70eae5c8b220fba5c2)

Fresh agents dispatched 2026-10-05 by the caller (Claude Code, Opus 5.5) with only the workspace
root, their own packet path and the verbatim question (closed-book: question only). Returns are
copied verbatim from the task notifications.

## Blind solver A (blind-solver, packet solver-1)

answer: **−$318 million** (Rapid and Molecular Diagnostics reported sales fell from $1,885M in 2H25 to $1,567M in 1H26)

confidence: high

path:
1. **How the 2026 business is defined.** D10, page 4 footnote (also D08, page 3): "*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business." Exact Sciences sales are shown separately as Cancer Diagnostics, so they are not part of this business.
2. **1H26 figure.** D10, page 4 table "Sales 1H26 ($ in millions) … Rapid/Molecular Diagnostics": U.S. 858, International 709, "Total reported … 1,567". The quarters agree: 1Q26 is 812 (D08, page 3, "Total reported 2,180 1,272 96 812") and 2Q26 is 755 (D10, "Total reported 3,092 1,418 919 755"). 812 + 755 = 1,567.
3. **3Q25 under the old structure.** D04, page 3, "Sales 3Q25 … Total Core Laboratory Molecular Point of Care Rapid Diagnostics … Total reported 2,253 1,364 131 158 600". The three businesses now combined add to 131 + 158 + 600 = **889**. Check: 1,364 + 889 = 2,253.
4. **4Q25 under the old structure.** D07, page 3, "Sales 4Q25 … Total reported 2,457 1,461 141 158 697". 141 + 158 + 697 = **996**. Check: 1,461 + 996 = 2,457.
5. **2H25 total.** 889 + 996 = **1,885**.
   - Second route: full-year 2025 (D07 12M25 "Total reported 8,937 5,360 517 606 2,454") gives 517 + 606 + 2,454 = 3,577. 1H25 (D03 "Total reported 4,227 2,535 245 290 1,157") gives 245 + 290 + 1,157 = 1,692. 3,577 − 1,692 = 1,885, which matches.
6. **The 2026 releases restate 2025 the same way.** The new structure's 2025 figures equal the simple sum of the three old businesses:
   - 1H26 vs 1H25: 1,567 / 1,692 − 1 = −7.39%. D10 prints "(7.4)".
   - U.S. 1H: 858 / 999 − 1 = −14.1%. D10 prints "(14.1)".
   - 1Q25 (D02: 122 + 142 + 613 = 877): 812 / 877 − 1 = −7.4%. D08 prints "(7.4)".
   - 2Q25 (D03: 123 + 148 + 544 = 815): 755 / 815 − 1 = −7.36%. D10 prints "(7.3)". This is a small rounding difference that probably comes from the unrounded underlying figures; it does not affect the answer.
7. **Change.** 1,567 − 1,885 = **−318** ($ millions), or about −16.9%.

minimal_documents: D10, D04, D07. An equally sufficient alternative is D10, D03, D07, using full-year 2025 minus 1H25. D08 duplicates D10's definition footnote and its 1Q26 figure. No two-document set works, because no single document gives both a 2H25 split and 1H26.

readings:
- **Old structure without Point of Care** (old "Rapid Diagnostics" plus "Molecular" only): 2H25 = (600 + 131) + (697 + 141) = 1,569, so the change would be −2. This goes against the question's "structure Abbott adopted in 2026", which the footnote says includes Point of Care, so I don't consider it a valid reading.
- **Comparable or FX-adjusted growth instead of reported sales:** the question asks for "reported sales", and no 2H25 comparable dollar figures are given anyway.
- **Percentage instead of dollars:** about −16.9%.

gaps:
- No document gives 2H25 directly or a recast 2H25 for the new structure. I derived it from the old-structure tables, and the 2026 growth rates confirm the derivation (fact 6).
- Coverage of the other documents:
  - D01 (2024 results) and D06 (a 114k-character document whose only grep hit was "as amended and restated") were not read beyond grep hits.
  - D05 (Exact Sciences deal announcement) and D11 (formula litigation settlement) were partly read; neither has segment tables.
  - D09 is a derivative litigation notice with no sales data.
- All documents are text extractions (manifest "method": "text", "pages": null), so there were no PDF pages to inspect. Every table row used was checked against its printed total.

contaminated: no

Packet text files used are in `D:\Dev\Docket\tasks\aq-00745\runs\q03-r1-v2-885ef14edf5cdb5848c63ddc993ab68088bf38ae671c9d70eae5c8b220fba5c2\solver-1\text\`:
- D10.txt (lines 187–203)
- D04.txt (line 179)
- D07.txt (lines 175, 206)
- D03.txt (lines 181, 214)
- D08.txt (lines 119, 137)
- D02.txt (line 129)

## Blind solver B (blind-solver, packet solver-2)

**Answer:** Under the 2026 structure, Rapid and Molecular Diagnostics reported sales fell by **−$318 million**, from $1,885 million in the second half of 2025 to $1,567 million in the first half of 2026.

```
answer: -318 (millions of dollars; $1,885M in 2H25 -&gt; $1,567M in 1H26)
confidence: high
path:
 1. How the 2026 business is defined. D10 (Q2 2026 release, 2026-07-16), Diagnostics footnote, text line 203: "*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business." D08 line 137 has the same footnote. So for 2025 the business = Molecular + Point of Care + Rapid Diagnostics.
 2. 1H26. D10 lines 187-191, "Sales 1H26 ... Rapid/Molecular Diagnostics": U.S. 858, International 709, "Total reported 5,272 2,690 1,015 1,567". The row sums: 2,690 + 1,015 + 1,567 = 5,272. Check against quarters: D08 1Q26 "Total reported 2,180 1,272 96 812" plus D10 2Q26 "Total reported 3,092 1,418 919 755" gives 812 + 755 = 1,567.
 3. 3Q25. D04 line 179 (Total, Core Lab, Molecular, Point of Care, Rapid Dx): "Total reported 2,253 1,364 131 158 600". 131 + 158 + 600 = 889.
 4. 4Q25. D07 line 175: "Total reported 2,457 1,461 141 158 697". 141 + 158 + 697 = 996.
 5. 2H25 = 889 + 996 = 1,885.
    Cross-check with full year minus first half. D07 line 206, 12M25 "Total reported 8,937 5,360 517 606 2,454": 517 + 606 + 2,454 = 3,577. D03 line 214, 1H25 "Total reported 4,227 2,535 245 290 1,157": 245 + 290 + 1,157 = 1,692. 3,577 − 1,692 = 1,885. Same result.
    Geographic check: U.S. 2H25 = (36+111+373) + (39+107+445) = 1,111, and 858 − 1,111 = −253. International 2H25 = (95+47+227) + (102+51+252) = 774, and 709 − 774 = −65. −253 + (−65) = −318.
 6. Check that the old-to-new mapping is complete. D10 shows 1H26 Rapid/Molecular "Total reported ... (7.4)" vs 1H25. 1,567 / 1,692 − 1 = −7.39%, which matches. Core Lab 2,690 / 2,535 − 1 = +6.1%, which matches D10's 6.1. So no other products moved between Core Lab and Rapid/Molecular.
 7. Result: 1,567 − 1,885 = −318.
 Sources checked against the original files in docs\ (abt_ex991_2025-10-15.txt l.177, 2026-01-22.txt l.173, 2026-07-16.txt l.189, 2025-07-17.txt l.179/208); the figures are identical.
minimal_documents: D10 + D04 + D07. Alternative: D10 + D07 + D03 (12M25 minus 1H25). D08 could replace the footnote, but 1H26 or 2Q26 still needs D10. D07 + D10 alone gives only about −317 to −319, because 1H25 would have to be backed out of the rounded −7.4%.
readings:
 - Reported is the measure the question asks for. Comparable or organic bases do not apply.
 - The Point of Care business could be left out (Rapid Dx + Molecular only): 2H25 = 731 + 838 = 1,569, change = −2. The 2026 footnote explicitly includes Point of Care, so this reading is not defensible.
 - The direction could be read in reverse (2H25 minus 1H26): +318 in size, but the question asks for the change "from" 2H25 "to" 1H26, so the sign is negative.
gaps: No Dnn.layout.txt files exist in text\, and the sources are .txt rather than PDFs, so I could not inspect any PDF page. No extraction problems: every decisive row sums to its total. Abbott did not publish a restated 2H25 figure for the new business, so 2H25 is built from the legacy business lines using the 2026 footnote, and the 1H25 consistency check in step 6 supports this. Unread: D01 and D02 beyond search hits (2024 and 1Q25 periods), D05 apart from a search (Exact Sciences deal announcement), D06 beyond its opening lines (By-Laws), and the non-Diagnostics sections of D03, D04, D07 and D08. D09 (derivative settlement notice) and D11 (NEC litigation release) were read in full and are not relevant. question.txt was deliberately not read.
contaminated: no
```

The files that support the answer are in `D:\Dev\Docket\tasks\aq-00745\runs\q03-r1-v2-885ef14edf5cdb5848c63ddc993ab68088bf38ae671c9d70eae5c8b220fba5c2\solver-2\text\`: D10.txt, D04.txt, D07.txt, with D03.txt and D08.txt as cross-checks.

## Closed-book solver (question only, no tools used)

answer: unknown
confidence: low
basis: I don't remember the "Rapid and Molecular Diagnostics" figures from Abbott's 2026 reporting structure, including the restated 2025 numbers. The first-half 2026 total depends on second-quarter 2026 results, released around July 2026, which is at or past my reliable knowledge. COVID testing trends and flu-season patterns could hint at a direction, but they can't give a dollar figure. It's also unclear whether Exact Sciences sales would be counted in this line, so I won't guess a number.
contaminated: no. The only extra context was an automatically attached account email, which has nothing to do with the question. There were no project instructions, memory, document excerpts, hints or earlier results, and I used no tools.

## Shortcut auditor (shortcut-auditor, packet shortcut)

answer: **−$318 million.** Rapid and Molecular Diagnostics reported sales fell from $1,885M in 2H25 to $1,567M in 1H26, a drop of about 16.9%.

verdict: clear

shortest_path:
1. **What the 2026 business includes.** D10 (abt_ex991_2026-07-16), footnote to the Diagnostics table, repeated word for word in D08: "Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business."
2. **1H26 sales.** D10's "Sales 1H26" table shows Rapid/Molecular Diagnostics total reported of **1,567** (U.S. 858, International 709). As a cross-check, D08's 1Q26 figure of 812 plus D10's 2Q26 figure of 755 also gives 1,567.
3. **3Q25 sales.** D04 (2025-10-15), "Sales 3Q25" total reported: Molecular 131, Point of Care 158, Rapid Diagnostics 600, which sums to **889**.
4. **4Q25 sales.** D07 (2026-01-22), "Sales 4Q25" total reported: Molecular 141, Point of Care 158, Rapid Diagnostics 697, which sums to **996**.
5. **2H25 sales.** 889 + 996 = **1,885**.
6. **Change.** 1,567 − 1,885 = **−318**.

Cross-checks:
- **Full year minus first half.** D07's 12M25 figures (517 + 606 + 2,454 = 3,577) minus D03's 1H25 figures (245 + 290 + 1,157 = 1,692) also give 1,885.
- **By geography.** 2H25 U.S. is 520 + 591 = 1,111 and International is 369 + 405 = 774. The changes are 858 − 1,111 = −253 and 709 − 774 = −65, which add to −318.
- **Quarters add to the year.** D02's 1Q25 (122 + 142 + 613 = 877), plus 815, 889 and 996, equals 3,577, matching 12M25.
- **No restatement beyond the merger of the three lines.** The growth rates Abbott printed match the simple sums:
  - D10 1H26 shows (7.4)%, and 1,567 / 1,692 − 1 = −7.39%.
  - D10 Core Laboratory shows 6.1%, and 2,690 / 2,535 − 1 = 6.1%.
  - D08 1Q26 shows (7.4)%, and 812 / 877 − 1 = −7.41%.
  - The 1H25 Diagnostics total of 4,227 in D10's reconciliation matches D03.

sufficient_documents:
- **Minimal set:** D10 + D07 + D04, or D10 + D07 + D03.
- **Substitution:** D08 repeats the structure footnote, but D10 is still needed for 2Q26/1H26.
- **Not sufficient:**
  - No single document gives the answer.
  - No document shows 2H25 figures under the 2026 structure.
  - D10 + D07 alone only approximates the answer: backing 1H25 out of D10's −7.4% gives 1,691–1,693, so the change could be anywhere from −317 to −319.

searches:
- **Terms searched in all 11 texts and the manifest:** Rapid, Molecular, Point of Care, aggregat, recast, reclassif, realign, "Beginning in 2026", "Rapid and Molecular", second half, 2H2, sequential, Diagnostic.
- **Read fully:** D08, D09, D10, D11.
- **Diagnostics sections read:** D02, D03, D04, D07 (D07 lines 1–240).
- **Checked by header or search only:**
  - D05 is the Exact Sciences deal announcement.
  - D06 is Abbott's by-laws.
  - D09 is the infant-formula derivative settlement notice.
  - D11 is the NEC (preterm formula) litigation release.
  - D01 covers 4Q24/12M24, outside the needed periods.
- **Shortcut search:** nothing that already states the answer turned up. There is no 2H25 total, no sequential half-year comparison for this business, and no recast table.

readings/gaps:
- **Leaving out Point of Care is a trap.** Rapid Diagnostics plus Molecular gives 2H25 = 731 + 838 = 1,569 and a change of −2. The question's "2026 structure" rules this out.
- **Rapid Diagnostics alone** gives 2H25 = 1,297 and a change of +270. Rejected.
- **Wrong period:** comparing against 1H25 instead of 2H25 gives 1,567 − 1,692 = −125.
- **Wrong basis:** comparable or excluding-FX figures were not asked for; the question says "reported".
- **Small rounding differences** in quarterly growth rates (2Q: 755/815 = −7.36% vs. the printed (7.3); 1Q U.S.: −13.73% vs. the printed (13.8)) fit unrounded underlying figures and do not change the result.
- **Unread parts:** D07 after line 240, the non-Diagnostics sections of D02/D03/D04, and the bodies of D01, D05 and D06 beyond the search hits. Searches found no recast or 2H data in them.
- **Difficulty risk, not a shortcut:** the arithmetic is simple. The real work is merging three legacy lines into the new business and building 2H25 from two quarterly releases.

Files:
- D:\Dev\Docket\tasks\aq-00745\runs\q03-r1-v2-885ef14edf5cdb5848c63ddc993ab68088bf38ae671c9d70eae5c8b220fba5c2\shortcut\text\D10.txt
- D:\Dev\Docket\tasks\aq-00745\runs\q03-r1-v2-885ef14edf5cdb5848c63ddc993ab68088bf38ae671c9d70eae5c8b220fba5c2\shortcut\text\D07.txt
- D:\Dev\Docket\tasks\aq-00745\runs\q03-r1-v2-885ef14edf5cdb5848c63ddc993ab68088bf38ae671c9d70eae5c8b220fba5c2\shortcut\text\D04.txt
- D:\Dev\Docket\tasks\aq-00745\runs\q03-r1-v2-885ef14edf5cdb5848c63ddc993ab68088bf38ae671c9d70eae5c8b220fba5c2\shortcut\text\D03.txt
- D:\Dev\Docket\tasks\aq-00745\runs\q03-r1-v2-885ef14edf5cdb5848c63ddc993ab68088bf38ae671c9d70eae5c8b220fba5c2\shortcut\text\D08.txt
- D:\Dev\Docket\tasks\aq-00745\runs\q03-r1-v2-885ef14edf5cdb5848c63ddc993ab68088bf38ae671c9d70eae5c8b220fba5c2\shortcut\text\D02.txt
